New study checks if IBD drug skyrizi seeps into breast milk

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must have received at least 2 doses of 360 mg risankizumab maintenance therapy every 8 weeks postpartum prior to start of participation in this study. * Participant is at least 5 weeks postpartum by Day 1. * Lactation is well established. The mother must be exclusively breastfeeding her infant (or not providing more than 1 supplemental bottle of formula/day) when enrolled in the study. * Diagnosis of crohn's disease (or ulcerative colitis upon approval of ulcerative colitis in the participants location) as established by the principal investigator Exclusion Criteria: * Participants who have major surgery planned during the conduct of the study (e.g., hip replacement, aneurysm removal, stomach ligation) * Participants with the following chronic or active infections: \-- Active HBV or HCV infection, defined as: * HBV: HBs Ag positive (+) test or detected sensitivity on the HBV DNA PCR qualitative test for participants who are HBc Ab positive (+) (and for HBs Ab positive \[+\] participants where mandated by local requirements). * HCV: HCV RNA detectable in any subject with HCV Ab. * Are infected with HIV, defined as confirmed positive anti-HIV Ab test. Note: In case a screened participant has a confirmed positive HIV Ab test,. * Active tuberculosis * Active systemic infection/clinically important infection during the last 2 weeks prior to the Baseline Visit as assessed by the investigator * Participants who have any of the following medical diseases or conditions: * Recent (within past 6 months) cerebrovascular accident or myocardial infarction; * History of an organ transplant which requires continued immunosuppression; * Active or suspected malignancy or history of any malignancy within the last 5 years except for successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix.